Great Debates in WM
Moderated by Carl Harrington- IWMF President
Rituxan Maintenance vs. No Maintenance
Morton Coleman MD – Weill Cornell Medical College vs. Stephen Ansell MD, PhD – Mayo Clinic, 2019 Ed Forum
Limited Treatment Duration vs. Continuous Pill
Edward Stadtmauer, MD – University of Pennsylvania vs. Jorge Castillo, MD – Dana Farber Cancer Institute, 2019 Ed Forum
The experts debate hot topics in long term treatment decisions for WM
Rare Complications of WM
Jorge Castillo, MD – Dana Farber Cancer Institute, 2019 Ed Forum
Discusses the following complications and their management: hyperviscosity, cryoglobulins, cold agglutinins, peripheral neuropathy, renal disease, and Bing-Neel syndrome.
The Revolution in WM Treatment: What’s on the Horizon
Jorge Castillo, MD – Dana Farber Cancer Institute, 2019 Ed Forum
Teaches us about the treatments that are on the horizon, including proteasome inhibitors: ixazomib with dexamethasone and rituximab as primary therapy, BTK inhibitors:, acalabrutinib, zanubrutinib, BGB-3111, vecabrutinib, venetoclax, combination ibrutinib and venetoclax as frontline therapy, CXCR4 inhibitors: ulocuplumab, ulixertinib, combination of ibrutinib and ulocuplumab for CXCR4WHIM, and anti-CD38 monoclonal antibody: daratumumab.
Treatments Around the Corner for WM
Discusses data from clinical trials for potential new treatments, such as ixazomib, dexamethasone, and rituximab as primary therapy, Venetoclax in previously treated WM, BTK inhibitor BGB-3111 in relapsed/refractory B-cell malignancies, Acalabrutinib (ACP-196), Ulocuplumab in CXCR4WHIM patients with WM, and Daratumumab in previously treated patients with WM
Upfront Treatment Approaches
Jorge Castillo, MD – Dana Farber Cancer Institute, IWWM9 Doctor-Patient Forum, 2016
Frontline Treatment Options for WM
Jorge Castillo, MD - Dana-Farber Cancer Institute, 2016 Ed Forum
Reviews the manifestations of WM disease, NCCN guidelines for initiation of treatment for WM, single agent treatments, combination therapies, maintenance, and new directions, including frontier clinical trials at Dana Farber Cancer Institute
Genomic-based Advances in WM
On March 6, 2016, Dr. Jorge Castillo spoke to the Philadelphia IWMF Support Group on Genomic-based Advances in WM. Dr. Castillo, of the Dana-Farber Cancer Institute, is one of the world’s leading clinicians for Waldenstrom’s macroglobulinemia, and provides a valuable perspective, especially since:
- There are approximately 1,500 WM patients diagnosed each year in the United States.
- Dr. Castillo sees approximately 750 WM patients each year!
- Most community oncologists see 0, 1, 2, or 3 WM patients in their career, Dr. Castillo probably sees more WM patients in a morning than most oncologists see in a lifetime.
This video is almost 2 hours in length.
No slides available
Current Treatment Options for Waldenstrom Macroglobulinemia
Current Treatment Options for WM provides a concise and informative review of both current and upcoming treatment options, along with the pros and cons of each.
Jorge J. Castillo, MD is Associate Professor at Harvard Medical School and Clinical Director of the Bing Center for Waldenstrom Macroglobulinemia at Dana-Farber Cancer Institute.
A Look into the Future: Treatments on the Horizon
A Look into the Future: New Treatments on the Horizon provides a concise and informative review of both current and upcoming treatment options, along with the pros and cons of each.
Jorge J. Castillo, MD is Associate Professor at Harvard Medical School and Clinical Director of the Bing Center for Waldenstrom Macroglobulinemia at Dana-Farber Cancer Institute.